首頁 > 市場調查報告書 > 製藥

眼科藥物

全球青光眼治療市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1421046

全球青光眼治療市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global Glaucoma Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年01月01日 | 出版商:

Value Market Research | 英文 231 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球青光眼治療市場需求預計將從 2023 年的 76.6 億美元增至 2032 年的近 121 億美元，2024-2032 年研究期間CAGR為 5.21%。

青光眼的治療涉及一系列醫療和手術干預措施，以管理和控制眼部疾病的進展。青光眼會導致視神經受損，這通常與眼壓 (IOP) 升高有關。作為不可逆性失明的主要原因，青光眼目前無法治癒。然而，治療策略的重點是防止視神經受到額外損傷並保留視力。

市場動態

全球青光眼盛行率不斷上升，特別是在老年人口中，各種因素推動了青光眼治療市場的發展。治療方案的技術進步，包括雷射療法和微創青光眼手術（MIGS），有助於擴大有效干預措施。意識的提高和早期檢測工作強調了對多樣化治療方案的需求，以滿足不同的患者需求。對 MIGS 等微創手術的偏好會影響患者的選擇，從而縮短復原時間並改善預後。醫療保健支出的增加、政府支持眼健康的舉措以及行業利益相關者之間的合作推動了青光眼治療的創新。競爭激烈的市場格局和持續的產品開發有助於引入新的和改進的治療方式。此外，擴大眼部保健服務的覆蓋範圍和教育措施進一步刺激了對青光眼治療的需求。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球青光眼治療市場的各個細分市場進行了包容性評估。青光眼治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

青光眼治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

依產品類型

前列腺素類似物 (PGA)
阿爾法激動劑
貝塔博克
膽鹼能
碳酸酐酶抑制
聯合用藥

按指示

角狀青光眼 (ACG)
開角型青光眼 (OAC)
繼發性青光眼
先天性青光眼
其他適應症

按銷售管道

醫院藥房
零售藥局
網上銷售

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲青光眼治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。青光眼治療市場的主要參與者包括諾華公司、輝瑞公司、默克公司、博士倫公司、艾爾建公司、百里高公司、梯瓦製藥工業有限公司、Akorn Inc、Mobius Therapeutics LLC。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：青光眼治療公司的競爭格局

青光眼治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

公司股份分析
市場集中度
Novartile AG

公司簡介
公司收入
產品
最近的發展

Pfizer Inc

公司簡介
公司收入
產品
最近的發展

Merck & Co. Ine

公司簡介
公司收入
產品
最近的發展

Bausch & Lomb Inc.

公司簡介
公司收入
產品
最近的發展

Allergan Plc

公司簡介
公司收入
產品
最近的發展

Perrigo Plc

公司簡介
公司收入
產品
最近的發展

Teva Pharmaceutical Industries Ltd

公司簡介
公司收入
產品
最近的發展

Akorn Inc

公司簡介
公司收入
產品
最近的發展

Mobius Therapeutics LLC

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112113373

The global demand for Glaucoma Treatment Market is presumed to reach the market size of nearly USD 12.1 BN by 2032 from USD 7.66 BN in 2023 with a CAGR of 5.21% under the study period 2024 - 2032.

The treatment of glaucoma involves a range of medical and surgical interventions to manage and control the progression of eye conditions. In glaucoma, the optic nerve is damaged, which is often linked to elevated intraocular pressure (IOP). As a leading cause of irreversible blindness, there is currently no cure for glaucoma. However, treatment strategies are focused on preventing additional damage to the optic nerve and preserving vision.

MARKET DYNAMICS

The Glaucoma treatment market is propelled by various factors responding to the increasing global prevalence of glaucoma, particularly among the aging population. Technological advancements in treatment options, including laser therapies and minimally invasive glaucoma surgeries (MIGS), contribute to the expansion of effective interventions. Rising awareness and early detection efforts emphasize the demand for diverse treatment options to address varying patient needs. The preference for minimally invasive procedures, such as MIGS, influences patient choices, offering reduced recovery times and improved outcomes. Increased healthcare expenditure, government initiatives supporting eye health, and collaborations among industry stakeholders drive innovation in glaucoma treatment. The competitive market landscape and continuous product development contribute to the introduction of new and improved treatment modalities. Additionally, expanding access to eye care services and educational initiatives further fuel the demand for glaucoma treatments.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of glaucoma treatment. The growth and trends of glaucoma treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the glaucoma treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

Prostaglandin Analogs (PGAs)
Alpha Agonnist
Beta Borkers
Cholinergic
Carbonic Anhydrase Inhibitom
Combined Medications

By Indication

Angle Clasura Glaucoma (ACG)
Open Angle Glaucuma (OAC)
Secondary Glaucoma
Congenital Glaucoma
Other Indications

By Sales Channel

Hospital Pharmacies
Retail Pharmacies
Online Sales

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Glaucoma Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Glaucoma Treatment market include Novartile AG, Pfizer Inc, Merck & Co. Ine, Bausch & Lomb Inc., Allergan Plc, Perrigo Plc, Teva Pharmaceutical Industries Ltd, Akorn Inc, Mobius Therapeutics LLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . GLAUCOMA TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product Type
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Sales Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL GLAUCOMA TREATMENT MARKET ANALYSIS BY PRODUCT TYPE

5.1 Overview by Product Type
5.2 Historical and Forecast Data
5.3 Analysis by Product Type
5.4 Prostaglandin Analogs (PGAs) Historic and Forecast Sales by Regions
5.5 Alpha Agonnist Historic and Forecast Sales by Regions
5.6 Beta Borkers Historic and Forecast Sales by Regions
5.7 Cholinergic Historic and Forecast Sales by Regions
5.8 Carbonic Anhydrase Inhibitom Historic and Forecast Sales by Regions
5.9 Combined Medications Historic and Forecast Sales by Regions

6 . GLOBAL GLAUCOMA TREATMENT MARKET ANALYSIS BY INDICATION

6.1 Overview by Indication
6.2 Historical and Forecast Data
6.3 Analysis by Indication
6.4 Angle Clasura Glaucoma (ACG) Historic and Forecast Sales by Regions
6.5 Open Angle Glaucuma (OAC) Historic and Forecast Sales by Regions
6.6 Secondary Glaucoma Historic and Forecast Sales by Regions
6.7 Congenital Glaucoma Historic and Forecast Sales by Regions
6.8 Other Indications Historic and Forecast Sales by Regions

7 . GLOBAL GLAUCOMA TREATMENT MARKET ANALYSIS BY SALES CHANNEL

7.1 Overview by Sales Channel
7.2 Historical and Forecast Data
7.3 Analysis by Sales Channel
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Online Sales Historic and Forecast Sales by Regions

8 . GLOBAL GLAUCOMA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE GLAUCOMA TREATMENT COMPANIES

9.1. Glaucoma Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF GLAUCOMA TREATMENT INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Novartile AG
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Pfizer Inc
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Merck & Co. Ine
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Bausch & Lomb Inc.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Allergan Plc
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Perrigo Plc
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Teva Pharmaceutical Industries Ltd
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Akorn Inc
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Mobius Therapeutics LLC
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments